On March 15, 2023 Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, reported that it is presenting a poster on its preclinical drug candidate BBT-207 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2023 annual meeting taking place on April 14-19 in Orlando, Florida (Press release, Bridge Biotherapeutics, MAR 15, 2023, View Source [SID1234628842]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following abstract is now available on AACR (Free AACR Whitepaper)’s website.
Presentation Title: BBT-207 is a broad-spectrum, highly potent, 4th generation EGFR TKI with enhanced activity to both sensitizing and treatment-emergent EGFR mutations including T790M and C797S
Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase and Phosphatase Inhibitors 1
Session Date & Time: Tuesday, April 18, 2023, 9:00 a.m. — 12:30 p.m.
Abstract Number: 4018
BBT-207, which is currently under IND-enabling preclinical development, is an internally discovered fourth-generation EGFR TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) with potent preclinical activity against a broad range of EGFR mutations including C797S in non-small cell lung cancer (NSCLC). The preclinical activity profile of BBT-207 allows it to be positioned in earlier-line settings for first, second and third generation EGFR TKI resistant patients, with the potential to treat or prevent brain metastases.
During last year’s AACR (Free AACR Whitepaper) poster presentation, the company presented preclinical data showing the potent anti-tumor efficacy of BBT-207, observed through both in vitro and in vivo studies. This year, the company will discuss the anti-tumor efficacy in tumor models with a broad range of EGFR mutations. Further, the poster will provide updated in vivo data on brain metastasis inhibition.
"Following last year’s AACR (Free AACR Whitepaper) poster presentation, we are excited to showcase the most current data from newly conducted preclinical efficacy studies, which showed extended survival rates in NSCLC models with EGFR mutations," said Jimmy Jin. M.D., Ph.D., Bridge Biotherapeutics Head of Discovery Biology. "We believe BBT-207 has the potential to be a broad-spectrum fourth-generation EGFR TKI, with the capacity to further augment treatment through combinations."
Bridge Biotherapeutics plans to initiate the Phase 1 clinical study of BBT-207, focusing on the treatment of advanced non-small cell lung cancer patients, in the first half of the year.